SEC Filing Summary: Synta Pharmaceuticals Corp. (8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Synta Pharmaceuticals Corp. on January 8, 2010. The filing discloses the entry into a material definitive agreement regarding a public offering of common stock. Note: The request metadata referenced "Madrigal Pharmaceuticals," but the filing text explicitly identifies the registrant as Synta Pharmaceuticals Corp.
Key Financial Metrics and Transaction Details
- Offering Size: 5,555,556 shares of common stock.
- Offering Price: $4.50 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 833,333 additional shares.
- Expected Net Proceeds: Approximately $23.1 million (excluding over-allotment exercise).
- Underwriters: Lazard Capital Markets LLC (sole book-running manager) and RBC Capital Markets Corporation (co-manager).
- Closing Date: Expected January 13, 2010, subject to customary conditions.
Material Changes
The filing reports a material change in the company's capital structure through the execution of an underwriting agreement for a new equity offering. No comparative financial performance data (revenue, profit, cash flow) is provided in this specific filing as it is a transactional report rather than a periodic financial statement.
Outlook, Risks, and Management Commentary
The company issued a press release on January 8, 2010, announcing the pricing of the offering. The underwriting agreement contains customary representations, warranties, indemnification obligations, and termination provisions. The filing includes a legal opinion regarding the legality of the share issuance. No specific operational outlook or risk factors beyond standard underwriting terms are detailed in the text of this report.
Investor Verification Checklist
- Verify the final closing date of the offering (expected January 13, 2010).
- Confirm whether the underwriters exercised the 833,333 share over-allotment option.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification and termination clauses.
- Check the press release (Exhibit 99.1) for management's stated use of proceeds.
- Confirm the final net proceeds after all underwriting discounts and expenses are deducted.